Market Overview

UPDATE: Canaccord Genuity Raises PT to $44 on Aegerion Pharmaceuticals on Encouraging Sales Data

Related AEGR
Meet The Biopharma Stock That Lost 34% Last Week
Midday Losers From October 31: Aegerion Pharmaceuticals, Bottomline Technologies, Digital Globe

Canaccord Genuity maintained Aegerion Pharmaceuticals (NASDAQ: AEGR) with a Buy rating and raised the price target from $36.00 to $44.00.

Canaccord Genuity commented, "On the Q4 EPS call, AEGR provided metrics on the first six weeks of the Juxtapid launch in HoFH. The key takeaway was 400+ vs. 1800-targeted U.S. physicians have been REMS-trained (expected to translate into scripts 1-8 weeks post) and have written 85 new scripts globally (“vast majority” in the U.S. – Brazil and Turkey may be active on a named-patient basis). Given the strong early launch progress, we question whether guidance of 250-300 patients on drug exiting 2013 and $15M-25M in 2013 revenue is conservative."

Aegerion Pharmaceuticals closed at $36.12 on Wednesday.

Latest Ratings for AEGR

DateFirmActionFromTo
Oct 2014NeedhamDowngradesBuyHold
Oct 2014JefferiesDowngradesBuyHold
Oct 2014JP MorganDowngradesOverweightNeutral

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (AEGR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional